

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 February 2001 (01.02.2001)

PCT

(10) International Publication Number
WO 01/07065 A3

(51) International Patent Classification⁷: **A61K 38/51**,
C12N 15/60, 9/88, A61K 48/00, A61P 7/00

(21) International Application Number: PCT/DK00/00425

(22) International Filing Date: 27 July 2000 (27.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 1999 01071 27 July 1999 (27.07.1999) DK
PA 2000 00667 19 April 2000 (19.04.2000) DK

(71) Applicant (for all designated States except US): **HEME-BIOTECH A/S** [DK/DK]; Roskildevej 12 C, DK-3400 Hillerød (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GELLERFORS**, Pär [SE/SE]; Lagmannsvägen 13, S-181 63 Lidingö (SE). **FOGH**, Jens [SE/DK]; Bjergagervej 37, DK-3540 Lyngø (DK).

(74) Agent: **PLOUGMANN, VINGTOFT & PARTNERS** A/S; Sankt Annæ Plads 11, P.O. Box 3007, DK-1021 Copenhagen K (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

(88) Date of publication of the international search report:
2 August 2001

Date of publication of the amended claims:
20 September 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES

(57) Abstract: A method for production of rhPBGD in high scale and use of rhPBGD in a method for treatment or prophylaxis of disease caused by deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway. The method comprising administering, to the subject, an effective amount of one or more catalyst which is said enzyme or an enzymatically equivalent part or analogue thereof prefeable in combination with a gene therapy of a mutation related to the catalyst. The disease is selected from the group consisting of acute intermittent porphyria (AIP), ALA deficiency porphyria (ADP), Porphyria cutanea tarda (PCT), Hereditary coproporphyria (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP). The catalyst is one or more enzymes selected from the group consisting of delta-aminolevulinic acid synthetase, delta-aminovulnic acid dehydratase (ALAD), porphobilinogen deaminase (PBGD), uroporphyrinogen III cosynthetase, uroporphyrinogen decarboxylase, coproporphyrinogen oxidase, protoporphyrinogen oxidase, and ferrochelatase, or an enzymatically equivalent part or analogue thereof. In addition the invention relates to the use of rhPBGD. The invention also relates to an expression plasmid pExp1-M2-BB (seq. ID No.1) and to use of a DNA fragment, the EcoR I - Hind III linear fragment (seq. ID No. 2), used for transformation in the hemC disruption strategy for production of rhPBGD expressed in *E. coli*.

WO 01/07065 A3

AMENDED CLAIMS

[received by the International Bureau on 12 March 2001 (12.03.01);
original claims 1-57 replaced by amended claims 1-53 (7 pages)]

1. The use of an effective amount of one or more catalysts which is/are enzyme(s) belonging to the heme biosynthetic pathway, or an enzymatically equivalent part or
5 analogue thereof, together with a pharmaceutically acceptable carrier, for the preparation of a pharmaceutical composition for treatment or prophylaxis of a disease caused by a deficiency, in a subject, of an enzyme belonging to the heme biosynthetic pathway.
2. The use according to claim 1, wherein the disease is selected from the group consisting
10 of
acute intermittent porphyria (AIP),
ALA deficiency porphyria (ADP),
Porphyria cutanea tarda (PCT),
Hereditary coproporphyria (HCP),
15 Harderoporphyria (HDP),
Variegata porphyria (VP),
Congenital erythropoietic porphyria (CEP),
Erythropoietic protoporphyria (EPP), and
Hepatoerythropoietic porphyria (HEP).
20
3. The use according to claim 1, wherein the catalyst is one or more enzymes selected from the group consisting of
delta-aminolevulinic acid synthetase,
delta-aminolevulinic acid dehydratase (ALAD),
25 porphobilinogen deaminase (PBGD),
uroporphyrinogen III cosynthetase,
uroporphyrinogen decarboxylase,
coproporphyrinogen oxidase,
protoporphyrinogen oxidase, and
30 ferrochelatase,
or an enzymatically equivalent part or analogue thereof.
4. The use according to claim 1, wherein the disease is AIP and the enzyme is PBGD or an enzymatically equivalent part or analogue thereof, preferably in combination with
35 ALAD.

5. The use according to claim 1, wherein the catalyst is a recombinant form of the enzyme belonging to the heme biosynthetic pathway or of the enzymatically equivalent part or analogue thereof.

5

6. The use according to any of the preceding claims, wherein the pharmaceutical composition is prepared to be administered by a route selected from the group consisting of the intravenous route, the intraarterial route, the intracutaneous route, the subcutaneous route, the oral route, the buccal route, the intramuscular route, the anal route, the transdermic route, the intradermal route, and the intratechal route.

10

7. The use according to any of the preceding claims, wherein the catalyst is formulated in an isotonic solution, such as 0.9% NaCl and 10-50 mM Sodium phosphate pH 6.50 to 8 or Sodium phosphate, glycine, mannitol or the corresponding potassium salts.

15

8. The use according to claim 7, wherein the catalyst is lyophilised.

9. The use according to claim 8, wherein the catalyst is sterile filtered.

10. The use according to any of the preceding claims, wherein the catalyst is formulated as lipid vesicles comprising phosphatidylcholine or phosphatidylethanolamine or combinations thereof.

20

11. The use according to any of the preceding claims, wherein the catalyst is incorporated into erythrocyte ghosts.

25

12. The use according to any of the preceding claims, wherein the catalyst is formulated as a sustained release formulation involving biodegradable microspheres, such as microspheres comprising polylactic acid, polyglycolic acid or mixtures of these.

30

13. The use according to any of the preceding claims, wherein the catalyst is lyophilised in a two-compartment cartridge, where the catalyst will be in the front compartment and water for reconstitution in the rear compartment.

14. The use according to claim 13, wherein the two compartment cartridge is combined with an injection device to administer the catalyst either by a needle or by a needle-less (high pressure) device.

5 15. The use according to any of the preceding claims, wherein the catalyst is formulated in a physiological buffer containing an enhancer for nasal administration.

16. The use according to claim 1, wherein the catalyst is formulated as an oral formulation containing lipid vesicles, such as those comprising phosphatidylcholine,
10 phosphatidylethanolamine, or sphingomyeline, or dextrane microspheres.

17. The use according to claim 1, wherein the catalyst is formulated so as to enhance the half-life thereof in the subject's bloodstream.

15 18. The use according to claim 17, wherein the catalyst has a polyethylene glycol coating.

19. The use according to claim 17, wherein the catalyst is complexed with a heavy metal.

20. The use according to claim 1, wherein the catalyst is an enzymatically equivalent part
20 or analogue of the enzyme and exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

21. The use according to claim 20, wherein the catalyst is a small artificial enzyme or an organic catalyst which can polymerise porphobilinogen to hydroxymethylbilane
25

22. The use according to claim 1, wherein the catalyst is said enzyme formulated in such a manner that it exerts at least part of its enzymatic activity intracellularly upon administration to the subject.

30 23. The use according to claim 22, wherein the catalyst is tagged with specific carbohydrates or other liver cell specific structures for specific liver uptake.

24. The use according to claim 1, wherein the catalyst exerts substantially all its enzymatic activity extracellularly in the bloodstream.

35

25. The use according to claim 24, wherein the enzymatic activity of the catalyst on its relevant heme precursor results in a metabolic product which 1) either moves into the intracellular compartment and is converted further via the remaining steps of the heme biosynthetic pathway or 2) is excreted from the subject via urine and/or faeces.

5

26. The use according to claim 1, wherein the catalyst has been prepared by a method comprising

- a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid
- 10 sequence encoding the catalyst;
- b) transforming a compatible host cell with the vector;
- c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence; and
- d) recovering the expression product from the culture
- 15 and optionally subjecting the expression product to post-translational processing, such as in vitro protein refolding, enzymatic removal of fusion partners, alkylation of amino acid residues, and deglycosylation, so as to obtain the catalyst.

27. The use according to claim 1, wherein the catalyst has been prepared by liquid-phase

20 or solid-phase peptide synthesis.

28. The use according to claim 26 of the preceding claims, wherein the catalyst is free from any other biological material of human origin.

25 29. The use according to any claim 1, wherein the catalyst is to be administered at least once a day, such as 2, 3, 4, or 5 times daily.

30. The use according to claim 29 wherein the daily dosage is in the range of 0.01 – 1.0 mg/kg body weight per day, such as in the range of 0.05 – 0.5 mg/kg body weight per day.

30

31. The use according to claim 29, wherein the daily dosage is about 0.1 mg per kg body weight per day.

32. The use according to any of the preceding claims wherein the catalyst is a

35 recombinant form of the enzyme.

33. The use according to claim 32 wherein the catalyst is recombinant human PBGD based on any of Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-erythro PBGD 1.1.1).

5

34. The use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form to prepare, either alone or in a combination with a suitable genetic vector and other components, a composition that can be used for gene therapy of a patient having a mutation in the PBGD gene causing an enzyme defect.

10

35. The use according to claim 34, wherein the enzyme deficiency is selected from enzyme deficiencies resulting in a disease selected from the group of Acute Intermittent Porphyrin, (AIP), ALA deficiency porphyria (ADP), Porphyrin cutanea tarda (PCT), Hereditary coproporphyrin (HCP), Harderoporphyria (HDP), Variegata porphyria (VP), Congenital erythropoietic porphyria (CEP), Erythropoietic protoporphyria (EPP), and Hepatoerythropoietic porphyria (HEP).

15

36. The use according to claim 35 wherein the disease is Acute Intermittent Porphyrin, (AIP).

20

37. The use according to claims 34-36, wherein the human PBGD cDNA sequence is selected from the group of Seq. ID NO 3 (clone PBGD 1.1) or Seq. ID NO 4 (non-erythro PBGD 1.1.1).

25 38. The use according to any of claims 34-37 wherein the said genetic vector is selected from the group of plasmids, adenovirus, retrovirus or associated adenovirus.

39. The use according to claims 34-38 wherein the application of said formulation results in substantially normal PBGD activity measured as a normalisation in urinary and/or

30 serum levels of delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) compared to the levels before treatment or to a reduction in the frequency of attack of symptoms.

40. The use of a human PBGD cDNA sequence of either non-erythropoietic form or erythropoietic form to prepare either alone or in a combination with a suitable genetic

35 vector and other components a composition facilitating the treatment of a patient with

Acute Intermittent Porphyria (AIP) by correction of one of the specific point mutations identified causing AIP by gene therapy induced chimeraplasty gene repair.

41. The use according to claim 40 comprising a delivery system for transfection which is
5 based on the use of a non-viral vector formulated in a vehicle preparation comprising one or more components selected from cationic phospholipids, phospholipids, phospholipids mixed with neutral lipids, lictosylated PEI, liposomes liposomes comprising mixtures of natural phopholipids and neutral lipids.
- 10 42. A use according to claim 40 wherein the mutation is selected from Table A.
43. A catalyst which is an enzyme of the heme biosynthetic pathway selected from the group consisting of
delta-aminolevulinic acid synthetase,
15 delta-aminolevulinic acid dehydratase (ALAD),
porphobilinogen deaminase (PBGD),
uroporphyrinogen III cosythetase,
uroporphyrinogen decarboxylase,
coproporphyrinogen oxidase,
20 protoporphyrinogen oxidase, and
ferrochelataase,
or an enzymatically equivalent part or analogue thereof, for use as a medicament.
44. A catalyst according to claim 43, which is recombinant human PBGD based on any of
25 Seq. ID NO 3 (clone PBGD 1.1) and Seq. ID NO 4 (non-erythro PBGD 1.1.1).
45. An expression plasmid pExp1-M2-BB as shown in Seq. ID NO 1 for use in the expression of rhPBGD in E. coli.
- 30 46. A DNA fragment, EcoR I - Hind III linear fragment as shown in Seq. ID NO 2, capable of obtaining hemC-deletion in a host.
47. A production strain of rhPBGD obtained by use of the DNA fragment, EcoR I - Hind III linear fragment as shown in Seq. ID NO 2 to obtain hemC-deletion in the host JM105-H-
35 R6-C by homologous gene replacement and transforming the resulting strain with the

expression plasmid pExp1-M2-BB to yield the final production strain PBGD which is free from production of PBGD of non human origin (Accession No 12915).

48. A method for the preparation of rhPBGD by a method comprising

5

a) introducing, into a suitable vector, a nucleic acid fragment which includes a nucleic acid sequence encoding PBGD;

b) transforming a compatible host cell with the vector;

10 c) culturing the transformed host cell under conditions facilitating expression of the nucleic acid sequence;

d) recovering the expression product from the culture.

49. A method according to claim 48 further comprising a fermentation step.

15 50. A method according to claim 48 further comprising a purification step.

51. A method according to claim 50 wherein the purification is performed with a His-Tag (rhPBGD-His).

20 52. A rhPBGD having a stability of at least 6 weeks at 20°C, such as for at least 7 weeks, preferably for 8 weeks.

53. A rhPBGD having a stability resulting in a decrease in activity of less than 10% per month, such as less than 5%.

25

INTERNATIONAL SEARCH REPORT

Inte. onal Application No

PCT/00/00425

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/51 C12N15/60 C12N9/88 A61K48/00 A61P7/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE, CANCERLIT, AIDSLINE, EMBASE, LIFESCIENCES, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | GROSS U ET AL: "Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria" CELLULAR AND MOLECULAR BIOLOGY, US, TARRYTOWN, NY, vol. 43, no. 1, 1 February 1997 (1997-02-01), pages 29-35, XP002082339 ISSN: 0145-5680 the whole document | 1-57 |
| A | SASSA S: "Diagnosis and therapy of acute intermittent porphyria" BLOOD REVIEWS, GB, EDINBURGH, vol. 10, no. 1, 1 March 1996 (1996-03-01), pages 53-58, XP002082340 the whole document | 1-57 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

23 January 2001

Date of mailing of the international search report

30/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/DE 90/00425

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | <p>GRANDCHAMP B: "Acute intermittent porphyria" SEMINARS IN LIVER DISEASE, DE, STUTTGART, vol. 18, no. 1, 1 January 1998 (1998-01-01), pages 17-24, XP002082341 the whole document</p> | 1-57 |
| P, X | <p>WO 99 37325 A (FOGH JENS ; HEMEBIOTECH A S (DK); GELLERFORS PAER (SE)) 29 July 1999 (1999-07-29) the whole document</p> | 1-57 |

Information for patient family members

PCT/00/00425

Form PCT/SA/210 (patent family annex) (July 1992)